Cargando…

Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review

Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Li, Zhang, Zhengchao, Wang, Ting, Yuan, Leihong, Sun, Xiaoke, Su, Pengxiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505927/
https://www.ncbi.nlm.nih.gov/pubmed/37727211
http://dx.doi.org/10.3389/fonc.2023.1179595
_version_ 1785107011186196480
author Yan, Li
Zhang, Zhengchao
Wang, Ting
Yuan, Leihong
Sun, Xiaoke
Su, Pengxiao
author_facet Yan, Li
Zhang, Zhengchao
Wang, Ting
Yuan, Leihong
Sun, Xiaoke
Su, Pengxiao
author_sort Yan, Li
collection PubMed
description Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly important for clinical management of patients. Conventional imaging examinations such as MRI and CT cannot accurately diagnose the pathological stages of advanced PCa, especially metastatic lymph node (LN) stages. As a result, developing an accurate molecular targeted diagnosis is crucial for advanced PCa. Prostate specific membrane antigen (PSMA) is of great value in the diagnosis of PCa because of its specific expression in PCa. At present, researchers have developed positron emission tomography (PET) targeting PSMA. A large number of studies have confirmed that it not only has a higher tumor detection rate, but also has a higher diagnostic efficacy in the pathological stage of advanced PCa compared with traditional imaging methods. This review summarizes recent studies on PSMA targeted PET in PCa diagnosis, analyzes its value in PCa diagnosis in detail, and provides new ideas for urological clinicians in PCa diagnosis and clinical management.
format Online
Article
Text
id pubmed-10505927
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105059272023-09-19 Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review Yan, Li Zhang, Zhengchao Wang, Ting Yuan, Leihong Sun, Xiaoke Su, Pengxiao Front Oncol Oncology Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly important for clinical management of patients. Conventional imaging examinations such as MRI and CT cannot accurately diagnose the pathological stages of advanced PCa, especially metastatic lymph node (LN) stages. As a result, developing an accurate molecular targeted diagnosis is crucial for advanced PCa. Prostate specific membrane antigen (PSMA) is of great value in the diagnosis of PCa because of its specific expression in PCa. At present, researchers have developed positron emission tomography (PET) targeting PSMA. A large number of studies have confirmed that it not only has a higher tumor detection rate, but also has a higher diagnostic efficacy in the pathological stage of advanced PCa compared with traditional imaging methods. This review summarizes recent studies on PSMA targeted PET in PCa diagnosis, analyzes its value in PCa diagnosis in detail, and provides new ideas for urological clinicians in PCa diagnosis and clinical management. Frontiers Media S.A. 2023-09-01 /pmc/articles/PMC10505927/ /pubmed/37727211 http://dx.doi.org/10.3389/fonc.2023.1179595 Text en Copyright © 2023 Yan, Zhang, Wang, Yuan, Sun and Su https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yan, Li
Zhang, Zhengchao
Wang, Ting
Yuan, Leihong
Sun, Xiaoke
Su, Pengxiao
Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
title Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
title_full Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
title_fullStr Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
title_full_unstemmed Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
title_short Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
title_sort application of targeted diagnosis of psma in the modality shift of prostate cancer diagnosis: a review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505927/
https://www.ncbi.nlm.nih.gov/pubmed/37727211
http://dx.doi.org/10.3389/fonc.2023.1179595
work_keys_str_mv AT yanli applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview
AT zhangzhengchao applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview
AT wangting applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview
AT yuanleihong applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview
AT sunxiaoke applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview
AT supengxiao applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview